Solid Biosciences (NASDAQ:SLDB) COO Sells $243,245.24 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 37,771 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $243,245.24. Following the sale, the chief operating officer owned 116,753 shares of the company’s stock, valued at $751,889.32. This represents a 24.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Solid Biosciences Trading Down 0.5%

SLDB stock traded down $0.03 during midday trading on Monday, hitting $6.43. 1,032,732 shares of the company’s stock were exchanged, compared to its average volume of 984,289. Solid Biosciences Inc. has a 1-year low of $2.41 and a 1-year high of $7.37. The stock has a market capitalization of $500.96 million, a PE ratio of -2.58 and a beta of 2.67. The business has a 50-day simple moving average of $5.75 and a two-hundred day simple moving average of $5.71.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, research analysts expect that Solid Biosciences Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SLDB has been the topic of a number of recent research reports. Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Chardan Capital restated a “buy” rating and issued a $15.00 price objective on shares of Solid Biosciences in a research report on Tuesday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Wednesday, January 14th. Finally, Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.70.

Institutional Trading of Solid Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in shares of Solid Biosciences in the 1st quarter worth about $418,000. Goldman Sachs Group Inc. grew its stake in shares of Solid Biosciences by 32.2% in the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock valued at $667,000 after buying an additional 43,910 shares in the last quarter. Woodline Partners LP acquired a new position in Solid Biosciences during the 1st quarter worth approximately $2,338,000. Blair William & Co. IL purchased a new position in Solid Biosciences in the 2nd quarter worth approximately $807,000. Finally, ProShare Advisors LLC acquired a new stake in Solid Biosciences in the second quarter valued at approximately $80,000. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of “Moderate Buy,” which may support demand despite near-term weakness. Analyst Rating Article
• Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
• Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.